When did VITEK 2 AST-Gram Positive Linezolid ( =8 µg/mL) receive FDA 510(k) clearance?

VITEK 2 AST-Gram Positive Linezolid ( =8 µg/mL) received FDA 510(k) clearance on 2022-02-04, under 510(k) number K212849.

FDA 510(k)

VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL)

N.º K: K212849 · 2022-02-04

SolicitanteBiomérieux, Inc.

Fecha de decisión2022-02-04

Código de productoLON

Comité asesorMI

DecisiónSubstantially Equivalent

Resumen del dispositivo

VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL) is the device name listed in this FDA 510(k) record. The listed applicant is Biomérieux, Inc.. It received FDA 510(k) clearance on 2022-02-04 under 510(k) number K212849. The device is classified under product code LON. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

Preguntas frecuentes

What is the VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL)?

VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL) is a medical device that received FDA 510(k) clearance on 2022-02-04. The listed applicant is Biomérieux, Inc.. The 510(k) number is K212849.

When did VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL) receive FDA 510(k) clearance?

VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL) received FDA 510(k) clearance on 2022-02-04, under 510(k) number K212849.

Who is the listed applicant for VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL)?

The FDA 510(k) record lists Biomérieux, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL)?

The FDA product code for VITEK 2 AST-Gram Positive Linezolid (<=0.5 – >=8 µg/mL) is LON.

Ensayos clínicos relacionados

Los registros relacionados se emparejan automáticamente mediante nombres, códigos de producto u otros metadatos. Un emparejamiento no establece una relación clínica, científica, corporativa o regulatoria verificada; revise las fuentes oficiales enlazadas.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITING NCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITING NCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED NCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Dispositivos relacionados (Código: LON)

K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc.K260281VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)BIOMERIEUX K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc.K251713BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)Becton, Dickinson and Company K250447BD Phoenix™ Automated Microbiology System - GN Imipenem-relebactam (0.0625/4 - 16/4 µg/mL)Becton, Dickinson and Company K234012VITEK COMPACT PRObioMerieux, Inc.

Fuente oficial

Ver en la base de datos de la FDA →

Datos procedentes de la API abierta de la FDA. Para obtener la información más actualizada y autoritativa, consulte siempre el registro oficial.